| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Lion Bioscience Aktiengesellschaft |
| Im Neuenheimer Feld 515-517, Hieidelberg, Germany D-69120 |
| Business Description | The company is a pioneer in the field of enterprise-wide R&D; data analysis and information management systems and solutions for the life sciences and ultimately, the healthcare industry. |
| Offering Information Company has | |||
| Trading As | LEON (NASNTL) | Industry | High-Tech |
| Type of Stock Offered | American Depositary Receipts | Filing Date | 7/10/2000 |
| Domestic Shares Offered | 4,575,375 | Offer Date | 8/10/2000 |
| Foreign Shares Offered | 0 | Filing Range | $35.25 - $41.92 |
| Company Shares | 4,575,375 | Offer Price | $39.68 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $2.777 |
| Gross Proceeds | $181,567,358 | Selling | - - |
| Expenses | - - | Reallowance | - - |
| Post-IPO Shares | 17,647,875 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Morgan Stanley Dean Witter | Lead Manager | (212) 761-5900 |
| Deutsch Banc Alex. Brown | Co-manager | (410) 727-1700 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 3/31/2000 | ||||||
| Revenues | - | - | - | - | 9.752 | - | - |
| Income from Oper. | - | - | - | - | -12.037 | - | - |
| Net Income | - | - | - | - | -12.049 | - | - |
| E.P.S | - | - | - | - | -13.210 | - | - |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -4.49 | - | - | ||||
| Cash Flow - Inv. | -19.18 | - | - | ||||
| Cash Flow - Fin. | 29.21 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/2000 | Financial Ratios | ||||
| Total Assets | 30.15 | Current Assets | 8.26 | Current Ratio | 0.94 |
| Total Liab. | 14.25 | Current Liab. | 8.75 | Debt Ratio | 47.24% |
| Total Equity | 15.91 | Working Cap. | -0.50 | Debt to Equity Ratio | 0.90 |
| Cash | 6.37 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to repay short-term indebtedness owed to Deutsche Bank and to fund working capital needs. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Sullivan & Cromwell |
| Bank's Law Firm | Davis, Polk & Wardwell |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Bayer AG | 10.71 | |
| European Biology Technology Laboratory | 6.30 | |
| Bear House Investment Co., Ltd | 6.12 | |
| Note: represents ownership of 5% or more prior to the offering. | ||